1.

BASIS OF PREPARATION

The summary consolidated financial statements are prepared in accordance with the requirements of the JSE Limited (JSE) for summary financial statements, and the requirements of the Companies Act applicable to summary financial statements. The JSE requires summary financial statements to be prepared in accordance with the framework concepts and the measurement and recognition requirements of International Financial Reporting Standards (IFRS) and the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council and to also, as a minimum, contain the information required by IAS 34: Interim Financial Reporting.

The accounting policies applied in the preparation of the consolidated financial statements from which the summary consolidated financial statements were derived are in terms of IFRS and are consistent with those accounting policies applied in the preparation of the previous consolidated annual financial statements, with the exception of the adoption of the amendments to IAS 16: Property, Plant and Equipment and IAS 41: Agriculture. These amendments have to be applied retrospectively and accordingly the reported results of the comparative year were restated. The restatements pertain to the reclassification of bearer plants from biological assets to property, plant and equipment, the transfer of the remaining noncurrent biological assets (being the produce) to current biological assets and the measurement of the reclassified assets under the appropriate accounting treatment. Refer to note 15 for further detail. The financial statements have been prepared under the supervision of the Chief Financial Officer, Neville Williams CA(SA).

The summary consolidated financial statements do not contain all the information and disclosures required in the consolidated financial statements. The summary consolidated financial statements have been extracted from the audited consolidated financial statements upon which PricewaterhouseCoopers Inc. has issued an unqualified report. The audited consolidated financial statements and the unqualified audit report are available for inspection at the registered office of the Company.

2.  HEADLINE EARNINGS RECONCILIATION 
   R million  30 June
2017 
30 June 
2016
Restated 
   Net profit for the year attributable to equity holders (earnings)  8 431  5 364 
   Plus/(minus)      
   –  Net impairment of equity accounted investments*  (302) 1 862 
   – Impairment of available-for-sale investments  – 
   –  Net impairment of property, plant and equipment  181  37 
   – Impairment of intangible assets*  –  644 
   –  Impairment of assets held for sale  – 
   –  Profit on sale and dilution of equity accounted investments**  (199) (2 349)
   –  Profit on sale of available-for-sale investments  –  (153)
   –  Recycling of foreign currency translation reserves  –  51 
   –  Net (surplus)/loss on disposal of property, plant and equipment  (110) 10 
   – Loss on disposal of biological agricultural assets  – 
   –  Non-headline earnings items included in equity accounted earnings of equity accounted investments  223  633 
       –  Net surplus on disposal of property, plant and equipment  (19) (27)
      –  Profit on the sale of investments  (325) (216)
      –  Net impairment of investments, assets and goodwill  668  809 
      –  Other non-recurring and capital items  (101) 67 
      –  Taxation effect of adjustments  (92) 
      –  Non-controlling interest  (13) (149) 
   Headline earnings  8 221  5 874 
   Once-off costs  –  788 
   Option remeasurement  (687) 730 
   Headline earnings, excluding once-off costs and option remeasurement***  7 534  7 392 
           
 *   For the year under review “Net impairment of equity accounted investments” primarily consists of a reversal of impairment of the investment in Grindrod of R478 million (2016: impairment of the investment in Grindrod of R1 861 million). For the previous year “Impairment of intangible assets” primarily consists of an impairment in RCL Foods’ Milling business amounting to R643 million.
** For the previous year “Profit on sale and dilution of equity accounted investments” primarily consists of a profit of R2 262 million realised on the dilution of Remgro’s interest in Mediclinic as part of the Al Noor transaction.
***

Included in headline earnings is a positive fair value adjustment of R687 million (2016: negative fair value adjustment of R730 million), relating to the change in value of the bondholders’ exchange option (accounted for as a derivative liability) of the bonds (“option remeasurement”) that were issued during March 2016 to partially refinance the foreign bridge funding that was raised for the Al Noor transaction. The bonds are exchangeable into Mediclinic plc shares and/or cash and fair value adjustments on the option (reflecting inter alia the movement in the underlying Mediclinic plc share price) are expected to cause volatility in headline earnings during its five-year term.

Included in headline earnings for the prior year are once-off transaction costs incurred with the Mediclinic rights issue and Al Noor Hospitals Group plc (Al Noor) transaction amounting to R788 million, of which R402 million was Remgro’s own costs and R386 million was Remgro’s share of Mediclinic’s transaction costs (“once-off costs”).


3.  EARNINGS AND DIVIDENDS 
   Cents  30 June
2017
30 June 
2016
Restated 
   Headline earnings per share       
   – Basic  1 485.5  1 119.6 
   – Diluted  1 479.5  1 115.0 
   Headline earnings per share, excluding once-off costs and option remeasurement       
   – Basic  1 361.3  1 409.0 
   – Diluted  1 355.5  1 404.4 
   Earnings per share       
   – Basic  1 523.4  1 022.4 
   – Diluted  1 517.2  1 018.5 
   Dividends per share       
   Ordinary  495.00  460.00 
   – Interim  194.00  185.00 
   – Final  301.00  275.00 
     
4. INVESTMENTS       
   R million       
   Equity accounted investments       
   Associates  75 392  73 418 
   Joint ventures  5 491  5 147 
      80 883  78 565 
   EQUITY ACCOUNTED INVESTMENT RECONCILIATION       
   Carrying value at the beginning of the year  78 565  57 831 
   Share of net attributable profit  7 545  6 250 
   Dividends received  (3 861) (3 900)
   Investment in Mediclinic  –  18 246 
   Dilutionary effects  196  1 886 
   Exchange rate differences  (4 947) (1 274)
   Grindrod impairment reversal/(impairment) 478  (1 861)
   Movements on reserves  2 256  1 350 
   Other movements  651  37 
   Carrying value at the end of the year  80 883  78 565 
     
5. LONG-TERM LOANS       
   20 000 Class A 7.7% cumulative redeemable preference shares  3 512  3 512 
   10 000 Class B 8.3% cumulative redeemable preference shares  4 382  4 382 
   Exchangeable bonds with an effective interest rate of 4.5%  5 650  6 380 
   Various other loans  3 127  3 672 
      16 671  17 946 
   Short-term portion of long-term loans  (225) (147)
      16 446  17 799 
           
6.  Additions to and replacement of property, plant and equipment  1 228  1 295 
           
7. Capital and investment commitments  1 247  1 999 
   (Including amounts authorised but not yet contracted for)      
           
8. Guarantees and contingent liabilities  26  241 
           
9. Dividends received from equity accounted investments set off against investments  3 861  3 900 
           
10. Dividends received from Associate Classified as asset Held for sale  –  149 
           
11. EQUITY ACCOUNTED INVESTMENTS       
   Share of after-tax profit of equity accounted investments       
   Profit before taking into account impairments, non-recurring and capital items  10 066  8 875 
   Net impairment of investments, assets and goodwill  (668) (809)
   Profit on the sale of investments  325  216 
   Other non-recurring and capital items  101  (67)
   Profit before tax and non-controlling interest  9 824  8 215 
   Taxation  (1 895) (1 709)
   Non-controlling interest  (384) (256)
      7 545  6 250 
           
12. Fair value remeasurements 
  The following methods and assumptions are used to determine the fair value of each class of financial instruments:
  • Financial instruments available-for-sale and investment in money market funds: Fair value is based on quoted market prices or, in the case of unlisted instruments, appropriate valuation methodologies, being discounted cash flow, liquidation valuation or actual net asset value of the investment.
  • Derivative instruments: The fair value of derivative instruments is determined by using appropriate valuation methodologies and mark-to-market valuations.

Financial instruments measured at fair value are disclosed by level of the following fair value hierarchy:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – Inputs (other than quoted prices included within level 1) that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices); and

Level 3 – Inputs for the asset or liability that are not based on observable market data (unobservable inputs). 

The following table illustrates the fair values of financial assets and liabilities that are measured at fair value, by hierarchy level:

   R million  Level 1  Level 2  Level 3  Total 
   30 June 2017             
   Assets             
   Available-for-sale  1 178  –  2 167  3 345 
   Derivative instruments  –  – 
   Investment in money market funds  5 888  –  –  5 888 
      7 066  2 167  9 234 
   Liabilities             
   Non-current derivative instruments  –  363  –  363 
   Current derivative instruments  –  13  49  62 
      –  376  49  425 
                 
                 
   30 June 2016             
   Assets             
   Available-for-sale  1 260  –  2 148  3 408 
   Derivative instruments  –  – 
   Investment in money market funds  1 050  –  –  1 050 
      2 310  2 148  4 466 
   Liabilities             
   Non-current derivative instruments  –  1 197  –  1 197 
   Current derivative instruments  –  63  54  117 
      –  1 260  54  1 314 
                 
  The following tables illustrate the reconciliation of the carrying value of level 3 assets and liabilities from the beginning to the end of the year:
   R million   30 June 
2017 
  30 June
2016
   Assets: Available-for-sale       
   Balances at the beginning of the year  2 148  1 591 
   Additions  119  174 
   Disposals  (67) (53)
   Exchange rate adjustments  (178) 236 
   Fair value adjustments through comprehensive income  145  200 
   Balances at the end of the year  2 167  2 148 
   Liabilities: Derivative instruments       
   Balances at the beginning of the year  54  – 
   Remeasurements  (5) – 
   Additions  –  54 
   Balances at the end of the year  49  54 
           
 

There were no transfers between the different levels.

Level 3 financial assets consist mainly of investments in the Milestone China entities (Milestone), the Kagiso Infrastructure Empowerment Fund (KIEF) and the Pembani Remgro Infrastructure Fund (PRIF) amounting to R1 554 million, R272 million and R246 million respectively. These investments are all valued based on the fair value of each investment’s underlying assets, which are valued using a variety of valuation methodologies. Listed entities are valued at the last quoted share price on the reporting date, whereas unlisted entities’ valuation methods include discounted cash flow valuations, appropriate earnings and revenue multiples.

Milestone’s fair value consists of listed investments (40%), cash and cash equivalents (4%) and unlisted investments (56%). Unlisted investments included at recent transaction prices in Milestone’s fair value amounted to R606 million, while its remaining eight unlisted investments were valued at R264 million and is considered to be immaterial. KIEF’s investments were valued using the discounted cash flow method or the agreed exit price. PRIF’s main assets are the investments in ETG Group and Nova Lumos. ETG Group was valued using appropriate revenue and earnings multiples based on peer group companies to determine a price-to-book valuation, while Nova Lumos was recently acquired and therefore valued at its cost price.

Changes in the valuation assumptions of the above unlisted investments will not have a significant impact on Remgro’s financial statements as the underlying assets of the funds in which Remgro made its investments are widely spread.

 
13.  RELATED PARTY TRANSACTIONS
 

 COMMUNITY INVESTMENT VENTURES HOLDINGS PROPRIETARY LIMITED (CIVH)

During September 2016 Remgro subscribed for an additional 12 353 shares in CIVH for a total amount of R329.3 million in terms of a CIVH rights issue. As a result of the share subscription, Remgro’s interest in CIVH increased marginally to 51.0% on 30 June 2017 (2016: 50.9%).

 CAPEVIN HOLDINGS LIMITED (CAPEVIN)

During May 2017 Remgro acquired a further 30 667 156 Capevin shares for a total amount of R264.5 million. This transaction increased Remgro’s effective interest in Capevin to 19.0% (2016: 15.6%).

 INVENFIN PROPRIETARY LIMITED (INVENFIN)

During July 2016 Remgro (through its wholly owned subsidiary, Invenfin) acquired a 30% stake in Dynamic Commodities Proprietary Limited (Dynamic Commodities) for R80.0 million. Dynamic Commodities is an export-focused company that produces high-quality frozen desserts, snacks and value-added “fresh frozen” fruit.

During August 2016, Invenfin also acquired a 30% stake in Joya Brands Proprietary Limited, a sweets manufacturer, for R50.2 million.

 OTHER

For other related party transactions refer to notes 4, 9, 10 and 11.

 
14.  EVENTS AFTER YEAR-END
 

 DISTELL GROUP LIMITED (DISTELL)

During June 2017 it was announced that Distell will restructure its multi-tiered ownership structure (the Proposed Transaction) and in order to give effect to the Proposed Transaction, Remgro will, through a number of inter-conditional steps, exchange its existing 50% shareholding in Remgro-Capevin Investments Proprietary Limited (RCI) for additional ordinary shares in Capevin Holdings Limited (Capevin) (RCI Exchange). Remgro currently holds 19.0% of the ordinary shares in Capevin and after the RCI Exchange, Remgro will hold 59.5% in Capevin. Following the RCI Exchange, Remgro will exchange its entire Capevin shareholding for ordinary shares in a new listed entity (New Distell), which entity will be substantially similar to the current Distell. Remgro will, in addition, also receive unlisted B shares in New Distell, which shares will be linked to those New Distell ordinary shares acquired by Remgro in virtue of the RCI Exchange, resulting in Remgro replicating RCI’s current 52.8% voting rights in Distell. The unlisted B shares will only carry voting rights in New Distell and will have no economic participation. The Proposed Transaction will have no impact on Remgro’s intrinsic asset value and Remgro will retain its economic interest in Distell. Post implementation of the Proposed Transaction, Remgro will, in aggregate, have voting rights of 56.0% in New Distell. The Proposed Transaction is still subject to a number of conditions precedent, inter alia Distell and Capevin shareholders’ approvals, which is expected to be on 27 October 2017, as well as the approval of the relevant competition authorities.

 RMI HOLDINGS LIMITED (RMI HOLDINGS)

On 19 September 2017 RMI Holdings declared its final dividend for the year ended 30 June 2017, which included an alternative to the cash dividend of either receiving a scrip distribution or reinvesting the cash dividend by subscribing for new RMI Holdings ordinary shares. Remgro has committed to reinvesting its cash dividend amounting to R292.3 million, by electing the reinvestment alternative, in order to receive 7 691 641 new RMI Holdings ordinary shares at R38.00 per share.

Other than the above-mentioned transactions, there were no other significant transactions subsequent to 30 June 2017.

 
15.  RESTATEMENT OF COMPARATIVE NUMBERS
 

The 30 June 2016 results were restated due to a change in accounting policy, as well as a rights issue.

 CHANGE IN ACCOUNTING POLICY

With effect from 1 July 2016 Remgro adopted the amendments to IAS 16: Property, Plant and Equipment and IAS 41: Agriculture. These amendments have to be applied retrospectively and accordingly the reported results of the comparative period were restated. The restatements pertain to the reclassification of bearer plants from biological assets to property, plant and equipment, the transfer of the remaining non-current biological assets (being the produce) to current biological assets and the measurement of the reclassified assets under the appropriate accounting treatment.

 RIGHTS ISSUE

During October 2016 Remgro completed a rights issue whereby 48 110 637 new ordinary shares and 3 550 635 new B ordinary shares were issued at a subscription price of R192.50 per share for a total consideration of R9 944.8 million. In terms of IAS 33 paragraph 26, an adjustment to the weighted average number of shares in issue for the comparative period is required as the shares were issued at a discount to the Remgro share price on the day before the announcement (being R243.29 per share). Consequently, the comparable weighted number of shares in issue was adjusted by 9 994 195 shares to account for the deemed dilutive effect of the rights issue.

 PRESENTATION OF INCOME STATEMENT

The fair value adjustment on the exchangeable bonds’ option was included in “Other net operating expenses” in the 2016 income statement. In order to improve disclosure this item is now shown separately.

 

 RESTATEMENT OF COMPARATIVE NUMBERS ON 1 JULY 2015

   R million  As at
1 July 2015
as previously
reported 
Adjustments  As at
1 July 2015
Restated 
   Impact on statement of financial position*          
   ASSETS          
   Property, plant and equipment  5 716  269  5 985 
   Non-current assets – Biological agricultural assets  550  (550) – 
   Current assets – Biological agricultural assets  549  281  830 
   Total assets  94 692  –  94 692 
              
  *  There was no impact on shareholders’ equity on 1 July 2015 as all affected entities elected to use the carrying value of bearer plants on that date as the deemed cost thereof as permitted by IFRS. 

 

 

RESTATEMENT OF COMPARATIVE NUMBERS FOR THE 2016 FINANCIAL YEAR

 

   R million  For the
year ended
30 June 2016
as previously
reported 
Adjustments  For the
year ended
30 June 2016
Restated 
   Impact on income statement          
   Depreciation  (670) (57) (727)
   Fair value adjustment on exchangeable bonds’ option  –  (730) (730)
   Other net operating expenses  (5 647) 726  (4 921)
   Taxation  17  21 
   Net profit for the year  5 453  (44) 5 409 
   Attributable to:          
   Equity holders (earnings) 5 386  (22) 5 364 
   Non-controlling interest  67  (22) 45 
         (44)   
   Impact on headline earnings          
   Headline earnings  5 887  (13) 5 874 
   Headline earnings, excluding once-off costs and option remeasurement  7 405  (13) 7 392 
   Impact on earnings per share (cents)         
   Headline earnings  1 143.9  (24.3) 1 119.6 
   Headline earnings, excluding once-off costs and option remeasurement  1 438.9  (29.9) 1 409.0 
   Earnings  1 046.6  (24.2) 1 022.4 
   Impact on statement of comprehensive income          
   Net profit for the year  5 453  (44) 5 409 
   Total comprehensive income for the year  8 032  (44) 7 988 
   Total comprehensive income attributable to:          
   Equity holders  7 965  (22) 7 943 
   Non-controlling interest  67  (22) 45 
         (44)   
   Impact on statement of cash flows          
   Cash flows from operating activities  1 457  22  1 479 
   Cash flows from investing activities  (18 745) (22) (18 767)
              

   R million  As at
30 June 2016
as previously
reported 
Adjustments  As at
30 June 2016
Restated 
   Impact on statement of financial position          
   ASSETS          
   Property, plant and equipment  6 292   208   6 500  
   Non-current assets – Biological agricultural assets  625   (625) – 
   Current assets – Biological agricultural assets  612   356   968 
   Total assets  109 161   (61) 109 100  
   LIABILITIES          
   Deferred taxation  1 640  (17) 1 623 
   Total liabilities  27 460  (17) 27 443 
   EQUITY          
   Distributable reserves  44 324  (22) 44 302 
   Non-controlling interest  2 835  (22) 2 813 
   Total equity  81 701  (44) 81 657